Literature DB >> 9377080

Qualitative and quantitative analysis of locus coeruleus neurons in Parkinson's disease.

E Bertrand1, W Lechowicz, G M Szpak, J Dymecki.   

Abstract

The analysis of qualitative changes in the locus coeruleus (LC) was performed on brains from 21 cases of Parkinson's disease. Eleven cases were selected for quantitative analysis of the loss of LC noradrenergic pigmented neurons. The qualitative studies revealed uneven dissemination of the noradrenergic cells loss of overall structure of the LC. Few preserved neurons showed degenerative changes. Extracellular neuromelanine granules, traces of dying neurons, were also observed. A weak astro- and microglia proliferation corresponded with neuronal loss. Lewy bodies were found in the LC in all cases. The quantitative analysis revealed that the average loss of adrenergic neurons in the LC accounts for about 70% in relation to the control group. The degenerative changes were observed in the whole LC, but they were most intensive in its caudal and next in the middle segment. The results suggest also that the degenerative process began in the middle segment and then it spread towards caudal segment of the LC as the stages of disease advanced.

Entities:  

Mesh:

Year:  1997        PMID: 9377080

Source DB:  PubMed          Journal:  Folia Neuropathol        ISSN: 1509-572X            Impact factor:   2.038


  37 in total

1.  Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration.

Authors:  Haeman Jang; David Boltz; Katharine Sturm-Ramirez; Kennie R Shepherd; Yun Jiao; Robert Webster; Richard J Smeyne
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-10       Impact factor: 11.205

2.  Changes in the mRNA levels of α2A and α2C adrenergic receptors in rat models of Parkinson's disease and L-DOPA-induced dyskinesia.

Authors:  Amal Alachkar; Jonathan M Brotchie; Owen T Jones
Journal:  J Mol Neurosci       Date:  2011-05-12       Impact factor: 3.444

3.  Evaluation of markers of oxidative stress, antioxidant function and astrocytic proliferation in the striatum and frontal cortex of Parkinson's disease brains.

Authors:  Rajeswara Babu Mythri; C Venkateshappa; G Harish; Anita Mahadevan; Uday B Muthane; T C Yasha; M M Srinivas Bharath; S K Shankar
Journal:  Neurochem Res       Date:  2011-04-12       Impact factor: 3.996

4.  Evidence for angiogenesis in Parkinson's disease, incidental Lewy body disease, and progressive supranuclear palsy.

Authors:  Brinda Desai Bradaric; Aditiben Patel; Julie A Schneider; Paul M Carvey; Bill Hendey
Journal:  J Neural Transm (Vienna)       Date:  2011-07-12       Impact factor: 3.575

Review 5.  Biomarkers for Parkinson's Disease: Recent Advancement.

Authors:  Sharvari Lotankar; Kedar S Prabhavalkar; Lokesh K Bhatt
Journal:  Neurosci Bull       Date:  2017-09-21       Impact factor: 5.203

6.  Intraneuronal dopamine-quinone synthesis: a review.

Authors:  D Sulzer; L Zecca
Journal:  Neurotox Res       Date:  2000-02       Impact factor: 3.911

Review 7.  Locus Coeruleus Modulates Neuroinflammation in Parkinsonism and Dementia.

Authors:  Filippo Sean Giorgi; Francesca Biagioni; Alessandro Galgani; Nicola Pavese; Gloria Lazzeri; Francesco Fornai
Journal:  Int J Mol Sci       Date:  2020-11-16       Impact factor: 5.923

Review 8.  Viral parkinsonism.

Authors:  Haeman Jang; David A Boltz; Robert G Webster; Richard Jay Smeyne
Journal:  Biochim Biophys Acta       Date:  2008-08-12

9.  The selective 5-HT1A receptor antagonist WAY-100635 inhibits neuronal activity of the ventromedial prefrontal cortex in a rodent model of Parkinson's disease.

Authors:  Jian Cao; Jian Liu; Qiao-Jun Zhang; Tao Wang; Shuang Wang; Ling-Na Han; Qiang Li
Journal:  Neurosci Bull       Date:  2007-11       Impact factor: 5.203

10.  Functional neuroanatomy of the noradrenergic locus coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and pharmacological manipulations and pathological alterations of locus coeruleus activity in humans.

Authors:  E R Samuels; E Szabadi
Journal:  Curr Neuropharmacol       Date:  2008-09       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.